Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Kidneys
- Disease
- Pharmaceuticals
- Dialysis
- Cancer
- Autoimmune
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26257
The amendment effectuated a transfer of regulatory responsibilities.
IPSCIO Record ID: 203264
Licensor grants an exclusive license under the Licensors Technology to use and import Hematide in the Field in the Licensed Territory, to Develop, use, sell, offer for sale, and import the Bulk API, or Hematide in bulk form, and/or the Product in the Field in the Licensed Territory, and to make and have made the Finished Product anywhere in the world for such Development or sale in the Field in the Licensed Territory.
Licensor grants to Licensee, during the Term, an exclusive license within the Licensed Territory to use and display the Product Trademarks and Licensors House Marks solely in the Promotional Materials and the Product Labeling in connection with the Commercialization of the Product within the Licensed Territory; provided that such license shall be co-exclusive with Licensor in the U.S. and further that Licensor may use such co-exclusive right solely for the Commercialization of the Product within the U.S. with Licensor.
“Product Trademark†means the mark “HEMATIDE†and any logos or symbols.
The technology refers to the Peptide, Dipeptide, Hematide, Product or their manufacture or use, or any other invention that is otherwise necessary or useful for the Development, Finished Manufacture or Commercialization of the Product.
Hematide, a synthetic, peptide-based, next-generation erythropoiesis- stimulating agent (ESA), is designed to stimulate the production of red blood cells. It is currently being evaluated in four Phase 2 clinical trials in the United States and Europe to treat anemia in chronic kidney disease (CKD) and cancer patients.
Hematide has a completely novel amino acid sequence that is unrelated to erythropoietin, a hormone that stimulates red blood cell formation, or to any other known naturally-occurring human sequences.
IPSCIO Record ID: 263343
This Amendment is to ratify existing Sub-Licenses and Supply Agreements.
The Parties further agree to complete a subsequent Amendment according to the binding terms and consistent with the Commercialization and Technology License Agreement – IV Triferic (IV License) executed on even date to the extent that it would not conflict with this Amendment.
Triferic® is a proprietary iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. The Company has developed two presentations of Triferic that are added to the dialysate, or Dialysate Triferic. Triferic is the first and only FDA-approved iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). It is believed Triferic addresses an important unmet need in the treatment of ongoing iron losses and anemia in ESRD patients. Triferics unique mode-of-action distinguishes it from conventional I.V. iron products because Triferic donates iron to transferrin, immediately, and completely, as soon as it enters the blood. The iron bound to transferrin is transported to the bone marrow to make hemoglobin. Triferic delivers approximately 5 & 7 mg of iron with every hemodialysis. Triferic is the first and only FDA-approved iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). We believe Triferic addresses an important unmet need in the treatment of ongoing iron losses and anemia in ESRD patients. Triferic s unique mode-of-action distinguishes it from conventional I.V. iron products because Triferic donates iron to transferrin, immediately, and completely, as soon as it enters the blood. The iron bound to transferrin is transported to the bone marrow to make hemoglobin. Triferic delivers approximately 5 & 7 mg of iron with every hemodialysis.
IPSCIO Record ID: 337709
ITP means immune thrombocytopenia where the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. ITP patients can suffer extraordinary bruising, bleeding and fatigue as a result of low platelet counts.
AIHA means autoimmune hemolytic anemia. It is is a rare, serious blood disorder where the immune system produces antibodies that result in the destruction of the bodys own red blood cells. Symptoms can include fatigue, shortness of breath, rapid heartbeat, jaundice or enlarged spleen.
